ATR and breast carcinoma: As well as paclitaxel, BAY-1816031 exhibits promising anti-proliferative activity against cancer cell lines when combined with ATR or PARP inhibitors and significantly reduces tumour size in breast cancer xenografts when combined with the PARP inhibitor olaparib [24].